OBJECTIVES: Examine associations among behaviors including substance use during sexual encounters, and transmitted HIV drug resistance in recently HIV-infected men who have sex with men (MSM). METHODS: Between 2002 and 2006, 117 recently HIV-infected MSM completed questionnaires regarding their 3 most recent sexual partners. Serum samples were tested for the presence of genotypic and phenotypic HIV drug resistance. Logistic regression analysis was used to assess the association of substance use, behaviors, and resistance to at least 1 class of HIV drugs. RESULTS: The mean age of participants was 35 years; 71% identified as white and 19% as Hispanic. Sixty (51%) reported substance use during sexual activity in the past 12 months. A total of 12.5% of 112 had genotypic drug resistance to at least 1 class of antiretroviral medications, and 14% of 117 had phenotypic drug resistance. Substances used during sexual activity associated with phenotypic drug resistance in multivariate models included any substance use (adjusted odds ratio [aOR] = 4.21, 95% confidence interval [CI]: 1.13 to 15.68), polysubstance use (aOR = 5.64, 95% CI: 1.62 to 19.60), methamphetamine (aOR = 4.00, 95% CI: 1.19 to 13.38), 3,4-methylenedioxy-N-methylamphetamine (MDMA)/Ecstasy (aOR = 7.16, 95% CI: 1.40 to 36.59), and gamma-hydroxyl butyrate (GHB) (aOR = 6.98, 95% CI: 1.82 to 26.80). The genotype analysis was similar. CONCLUSIONS: Among these recently HIV-infected MSM, methamphetamine use during sexual activity and use of other substances, such as MDMA and GHB, was associated with acquired drug-resistant virus. No other behaviors associated with acquisition of drug-resistant HIV.
OBJECTIVES: Examine associations among behaviors including substance use during sexual encounters, and transmitted HIV drug resistance in recently HIV-infectedmen who have sex with men (MSM). METHODS: Between 2002 and 2006, 117 recently HIV-infected MSM completed questionnaires regarding their 3 most recent sexual partners. Serum samples were tested for the presence of genotypic and phenotypic HIV drug resistance. Logistic regression analysis was used to assess the association of substance use, behaviors, and resistance to at least 1 class of HIV drugs. RESULTS: The mean age of participants was 35 years; 71% identified as white and 19% as Hispanic. Sixty (51%) reported substance use during sexual activity in the past 12 months. A total of 12.5% of 112 had genotypic drug resistance to at least 1 class of antiretroviral medications, and 14% of 117 had phenotypic drug resistance. Substances used during sexual activity associated with phenotypic drug resistance in multivariate models included any substance use (adjusted odds ratio [aOR] = 4.21, 95% confidence interval [CI]: 1.13 to 15.68), polysubstance use (aOR = 5.64, 95% CI: 1.62 to 19.60), methamphetamine (aOR = 4.00, 95% CI: 1.19 to 13.38), 3,4-methylenedioxy-N-methylamphetamine (MDMA)/Ecstasy (aOR = 7.16, 95% CI: 1.40 to 36.59), and gamma-hydroxyl butyrate (GHB) (aOR = 6.98, 95% CI: 1.82 to 26.80). The genotype analysis was similar. CONCLUSIONS: Among these recently HIV-infected MSM, methamphetamine use during sexual activity and use of other substances, such as MDMA and GHB, was associated with acquired drug-resistant virus. No other behaviors associated with acquisition of drug-resistant HIV.
Authors: R Stall; J P Paul; G Greenwood; L M Pollack; E Bein; G M Crosby; T C Mills; D Binson; T J Coates; J A Catania Journal: Addiction Date: 2001-11 Impact factor: 6.526
Authors: C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: Hanne Thiede; Linda A Valleroy; Duncan A MacKellar; David D Celentano; Wesley L Ford; Holly Hagan; Beryl A Koblin; Marlene LaLota; William McFarland; Douglas A Shehan; Lucia V Torian Journal: Am J Public Health Date: 2003-11 Impact factor: 9.308
Authors: Grant Colfax; Eric Vittinghoff; Marla J Husnik; David McKirnan; Susan Buchbinder; Beryl Koblin; Connie Celum; Margaret Chesney; Yijian Huang; Kenneth Mayer; Sam Bozeman; Franklyn N Judson; Kendall J Bryant; Thomas J Coates Journal: Am J Epidemiol Date: 2004-05-15 Impact factor: 4.897
Authors: N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Viktor von Wyl; Sabine Yerly; Jürg Böni; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Hansjakob Furrer; Amalio Telenti; Bernard Hirschel; Pietro L Vernazza; Enos Bernasconi; Martin Rickenbach; Luc Perrin; Bruno Ledergerber; Huldrych F Günthard Journal: Arch Intern Med Date: 2007-09-10
Authors: Radha Rajasingham; Matthew J Mimiaga; Jaclyn M White; Megan M Pinkston; Rachel P Baden; Jennifer A Mitty Journal: AIDS Patient Care STDS Date: 2011-11-09 Impact factor: 5.078
Authors: Iris Chen; Matthew B Connor; William Clarke; Mark A Marzinke; Vanessa Cummings; Autumn Breaud; Jessica M Fogel; Oliver Laeyendecker; Sheldon D Fields; Deborah Donnell; Sam Griffith; Hyman M Scott; Steven Shoptaw; Carlos del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Adam W Carrico; Lance M Pollack; Ronald D Stall; Starley B Shade; Torsten B Neilands; Thomas M Rice; William J Woods; Judith T Moskowitz Journal: Drug Alcohol Depend Date: 2011-11-15 Impact factor: 4.492
Authors: Pamina M Gorbach; Robert E Weiss; Robin Jeffries; Marjan Javanbakht; Lydia N Drumright; Eric S Daar; Susan J Little Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Lloyd A Goldsamt; Michael C Clatts; Monica M Parker; Vivian Colon; Renee Hallack; Maria G Messina Journal: AIDS Patient Care STDS Date: 2011-04-02 Impact factor: 5.078
Authors: Susan E Buskin; Giovanina M Ellis; Gregory G Pepper; Lisa M Frenkel; Steven A Pergam; Geoffrey S Gottlieb; Carrie Horwitch; Jeffrey F Olliffe; Karen Johnson; Peter Shalit; Corinne Heinen; Margot Schwartz; Robert W Wood Journal: J Acquir Immune Defic Syndr Date: 2008-10-01 Impact factor: 3.731